These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21617983)

  • 21. Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Porru D
    Eur Urol; 2009 Feb; 55(2):480. PubMed ID: 18583021
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.
    Liao CH; Kuo YC; Kuo HC
    Urology; 2013 May; 81(5):1030-3. PubMed ID: 23506731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand.
    Arnold EP
    BJU Int; 2001 Jan; 87(1):24-30. PubMed ID: 11121988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamsulosin and tolterodine in the medical expulsive therapy for intramural ureteral stones with vesical irritability: a prospective randomized study.
    Lv JL; Tang Ql
    Urolithiasis; 2013 Oct; 41(5):417-21. PubMed ID: 23963102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Wyndaele JJ
    BJU Int; 2012 Jul; 110(2 Pt 2):E143. PubMed ID: 22734513
    [No Abstract]   [Full Text] [Related]  

  • 31. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
    Cao Y; Wang Y; Guo L; Yang X; Chen T; Niu H
    Med Sci Monit; 2016 Jun; 22():1895-902. PubMed ID: 27260129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
    Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
    Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).
    Siami P; Seidman LS; Lama D
    Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.
    Maruyama I; Yonekubo S; Tatemichi S; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
    J Smooth Muscle Res; 2012; 48(5-6):115-24. PubMed ID: 23538508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical treatment of distal ureteral stones.
    Erturhan S; Erbagci A; Yagci F; Celik M; Solakhan M; Sarica K
    Urology; 2007 Apr; 69(4):633-6. PubMed ID: 17445639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
    Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
    Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
    Streng T; Andersson KE; Hedlund P; Gratzke C; Baroni E; D'Ambrosio D; Benigni F
    BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.